Massivemarkets

Nasdaq: PBLS · Listed Jun 10, 2026

Parabilis Medicines IPO

IPO price

$20.00

Parabilis Medicines (PBLS) priced its IPO at $20.00 a share and has traded on Nasdaq since Jun 10, 2026.

PBLS today$26.77+33.85%since IPO15-min delayed · as of 4:02:15 AM EST on Nov 19, 2026

See the PBLS quote

First trading day · Jun 10, 2026

IPO price 20.00VWAP 30.73first trade 33.35+66.75% from the IPO pricehigh 33.72$32.24volume · rising bars above the line, falling bars below283.82K12:454:00
IPO price
$20.00
above the range of $17 to $19
First trade
$33.35
+66.75% from the IPO price
First-day last trade
$32.24
+61.22% from the IPO price, regular session
Raise
$670M
before the underwriters' option

These numbers are from the first trading day, Jun 10, 2026.

How PBLS did against the market

PBLS against the market, from its first trade at 12:45 ET to the last trade of the session.

PBLS from its first trade
-3.31%
Against the market (QQQ)
-2.5 pts

PBLS fell 3.3% from its first trade to the last trade of the session. That is 2.5 points worse than the market.

Same-day moves do not show that PBLS caused them. The market is QQQ, the Nasdaq-100 ETF.

The debut race

PBLS against other big listings, as the percent change from each stock's own IPO price.

The first 30 trading days. Each point is the last regular-session trade of a day.

+50%+100%+150%+200%+250%IPOday 1day 5day 10day 15day 20day 25day 30Figma '25 +69.64%Reddit '24 +40.32%CoreWeave '25 +28.42%Arm '23 -3.06%Klarna '25 -7.33%PBLS +64.25%

The IPO scoreboard

PBLS against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.

PBLS against other big IPOs: the money raised, and the return from each IPO price at the first trade, at the last trade of day 1, and on day 5 and day 30.
IPORaisedFirst tradeDay 1 closeDay 1 close, as a barDay 5Day 30
Parabilis Medicines '26$670M+66.75%+61.22%+32.25%+64.25%
Figma '25$1.22B+157.58%+252.42%+173.64%+69.64%
Circle '25$1.05B+122.58%+168.45%+278.18%+622.98%
Reddit '24$748M+38.24%+47.97%+69.90%+40.32%
Arm '23$5.23B+10.00%+23.76%+3.63%-3.06%
Klarna '25$1.37B+30.00%+16.14%+13.73%-7.33%
CoreWeave '25$1.5B-2.50%+0.02%+34.32%+28.42%

Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.

The offering

The Parabilis Medicines IPO offers 33.5M shares to raise $670M, before any underwriters' option.

$15$17$18$19$21
Expected price range
$17 to $19
IPO price
$20.00
Shares offered
33.5M
Money raised
$670M
Listing date
Jun 10, 2026
Exchange
Nasdaq
Security
Ordinary Shares

Money raised, against the largest IPOs

  • Alibaba '14$21.77B
  • Facebook '12$18.41B
  • Rivian '21$11.93B
  • Uber '19$8.1B
  • Arm '23$5.23B
  • Parabilis Medicines$670M

Where PBLS ranks

Parabilis Medicines's market cap against the largest US-listed companies.

Market cap, against the largest US-listed companies

  • AAPL$5.12T
  • MSFT$3.77T
  • NVDA$3.65T
  • GOOGL$3.47T
  • AMZN$2.9T
  • TSM$1.88T
  • AVGO$1.69T
  • META$1.58T
  • TSLA$1.52T
  • BRK.B$1.22T
  • PBLS$3.57B

PBLS news

The latest news and headlines about Parabilis Medicines (PBLS).

Filings and the company

What Parabilis Medicines has disclosed to the SEC, and the basic facts about the listing.

8-K filings

Material events that Parabilis Medicines discloses to the SEC on Form 8-K.

  • Quarterly earningsNov 12, 2026

    On November 12, 2026, Parabilis Medicines, Inc. (the "Company") announced its financial results and business highlights for the quarter ended September 30, 2026.

  • Lease agreementNov 5, 2026

    On October 30, 2026, Parabilis Medicines, Inc. and LS 400/500 CDP, LLC entered into a Third Amendment of Lease, which amends the Lease regarding the Company's corporate headquarters located at 30 Acorn Park Drive, Cambridge, Massachusetts. The Amendment provides for an expansion, beginning on January 1, 2028, of the leased space by a total of 33,525 square feet at 20 Acorn Park Drive, an extension of the lease term through December 31, 2037, and options for further five-year extensions.

  • Executive compensation changeSep 2, 2026

    In connection with his departure from the Company, Dr. Benzaghou will receive severance benefits pursuant to the terms of his employment agreement with the Company.

  • Executive compensation changeAug 25, 2026

    In accordance with the Company's compensation program for non-employee directors, Mr. Tendler received an equity award consisting of a stock option to purchase 20,294 shares of the Company's common stock at an exercise price of $39.36 per share. The option award will vest in thirty-six substantially equal monthly installments over three years from the date of grant... Mr. Tendler will also receive an annual retainer of $40,000 for Board service and $7,500 for Science & Technology Committee service, each to be paid quarterly in arrears.

  • Investor presentationAug 13, 2026

    On August 13, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the investor relation page of the Company's website at https://parabilismed.com/. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

About Parabilis Medicines

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Ticker
PBLS
Exchange
Nasdaq
Market
stocks
Type
CS
Currency
USD
Industry
PHARMACEUTICAL PREPARATIONS
Listed
Jun 10, 2026
Security
Ordinary Shares
Company website

Frequently asked questions

What was the Parabilis Medicines IPO price?

$20.00 a share.

When did Parabilis Medicines go public?

Parabilis Medicines listed on Nasdaq on Jun 10, 2026 under the ticker PBLS.

How much did the Parabilis Medicines IPO raise?

$670M, before any underwriters' option.

How did Parabilis Medicines open on its first day?

PBLS first traded at $33.35, +66.75% from the IPO price of $20.00.

How did PBLS close on its first day?

Its last regular-session trade was $32.25, +61.22% from the IPO price of $20.00.

What was the PBLS first-day trading range?

$26.61 to $34.02 in the regular session.

How many PBLS shares traded on the first day?

5.32M shares in the regular session.

How many shares did Parabilis Medicines sell in its IPO?

33.5M shares.

How did PBLS do against the market on its first day?

PBLS fell 3.3% from its first trade to the last trade of the session. That is 2.5 points worse than the market (QQQ, the Nasdaq-100 ETF).

What exchange is PBLS listed on?

Parabilis Medicines lists on Nasdaq under the ticker PBLS.

Build with Massive

Get the PBLS data behind this page

The Massive endpoint behind each section of this page
What the page showsEndpoint
Offering terms and dates/vX/reference/ipos
Price/v3/snapshot
Chart, VWAP, and the market comparison/v2/aggs/ticker/PBLS/range/5/minute
Market cap/v3/reference/tickers/PBLS
News/v2/reference/news
Filings/vX/disclosures

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.